Jackson Blair Curtis

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 16

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,951

Underlying: Ordinary Shares · 685 shares

Expires not disclosed

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F6 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F13 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

F13 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 15

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,803

Underlying: Ordinary Shares · 2,741 shares

Expires 2033-02-23

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F12 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 14

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,690

Underlying: Ordinary Shares · 523 shares

Expires not disclosed

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F6 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F11 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

F11 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 13

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,344

Underlying: Ordinary Shares · 2,790 shares

Expires 2032-02-18

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F10 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 12

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,387

Underlying: Ordinary Shares · 380 shares

Expires not disclosed

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F6 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F9 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

F9 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 11

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,221

Underlying: Ordinary Shares · 3,102 shares

Expires 2031-02-22

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F8 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 10

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,680

Underlying: Ordinary Shares · 91 shares

Expires not disclosed

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F6 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 9

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,287

Underlying: Ordinary Shares · 1,534 shares

Expires 2030-02-20

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 8

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,989

Underlying: Ordinary Shares · 1,489 shares

Expires 2029-02-21

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 7

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,759

Underlying: Ordinary Shares · 759 shares

Expires 2028-02-16

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 6

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,699

Underlying: Ordinary Shares · 699 shares

Expires 2027-02-17

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 5

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,899

Underlying: Ordinary Shares · 899 shares

Expires 2026-03-01

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 4

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,969

Underlying: Ordinary Shares · 469 shares

Expires 2025-02-26

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 3

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,599

Underlying: Ordinary Shares · 599 shares

Expires 2024-03-03

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-23-007181 · form4.xml · derivative · entry 5

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,266

Underlying: Ordinary Shares · 34,266 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

SEC source: 0001127602-23-007181 · form4.xml · derivative · entry 4

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,062

Underlying: Ordinary Shares · 137,062 shares

Expires 2033-02-23

F3 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

SEC source: 0001127602-23-007181 · form4.xml · derivative · entry 3

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,007

Underlying: Ordinary Shares · 9,504 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

SEC source: 0001127602-23-007181 · form4.xml · nonDerivative · entry 2

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,117

SEC source: 0001127602-23-007181 · form4.xml · nonDerivative · entry 1

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,205

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-23-006514 · form4.xml · derivative · entry 11

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 4,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · derivative.exercise_date: This award is fully vested in accordance with its terms.

F5 · derivative.expiration_date: This award is fully vested in accordance with its terms.

SEC source: 0001127602-23-006514 · form4.xml · nonDerivative · entry 8

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,701

SEC source: 0001127602-23-006514 · form4.xml · nonDerivative · entry 7

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,113

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-23-006514 · form4.xml · derivative · entry 10

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,589

Underlying: Ordinary Shares · 4,589 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

SEC source: 0001127602-23-006514 · form4.xml · nonDerivative · entry 6

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,313

SEC source: 0001127602-23-006514 · form4.xml · nonDerivative · entry 5

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,279

F2 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 20, 2020 with a three-year performance period that ended on December 31, 2022 (the "2020 PRSUs"). The vesting of this portion of the 2020 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2020 PRSUs.

SEC source: 0001127602-23-006514 · form4.xml · nonDerivative · entry 4

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,193

SEC source: 0001127602-23-006514 · form4.xml · nonDerivative · entry 3

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,543

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-23-006514 · form4.xml · derivative · entry 9

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,167

Underlying: Ordinary Shares · 8,722 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

SEC source: 0001127602-23-006514 · form4.xml · nonDerivative · entry 2

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,954

SEC source: 0001127602-23-006514 · form4.xml · nonDerivative · entry 1

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,637

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-22-012413 · form4.xml · derivative · entry 3

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 49,999 shares

Expires 2022-05-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-22-012413 · form4.xml · nonDerivative · entry 2

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,915

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.50 to $29.76. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

SEC source: 0001127602-22-012413 · form4.xml · nonDerivative · entry 1

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,914

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001127602-22-006309 · form4.xml · derivative · entry 11

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,511

Underlying: Ordinary Shares · 9,503 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into ordinary shares on a one-for-one basis.

F6 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/22/2022.

F6 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/22/2022.

SEC source: 0001127602-22-006309 · form4.xml · nonDerivative · entry 6

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,915

SEC source: 0001127602-22-006309 · form4.xml · nonDerivative · entry 5

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,709

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into ordinary shares on a one-for-one basis.

SEC source: 0001127602-22-006309 · form4.xml · derivative · entry 10

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,800

Underlying: Ordinary Shares · 4,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into ordinary shares on a one-for-one basis.

F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020.

F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020.

SEC source: 0001127602-22-006309 · form4.xml · nonDerivative · entry 4

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,206

SEC source: 0001127602-22-006309 · form4.xml · nonDerivative · entry 3

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,618

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into ordinary shares on a one-for-one basis.

SEC source: 0001127602-22-006309 · form4.xml · derivative · entry 9

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,178

Underlying: Ordinary Shares · 4,589 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into ordinary shares on a one-for-one basis.

F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/20/2021.

F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/20/2021.

SEC source: 0001127602-22-006309 · form4.xml · nonDerivative · entry 2

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,818

SEC source: 0001127602-22-006309 · form4.xml · nonDerivative · entry 1

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,153

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into ordinary shares on a one-for-one basis.

SEC source: 0001127602-22-006309 · form4.xml · derivative · entry 8

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,889

Underlying: Ordinary Shares · 34,889 shares

Expires not disclosed

F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/18/2023.

F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/18/2023.

SEC source: 0001127602-22-006309 · form4.xml · derivative · entry 7

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,554

Underlying: Ordinary Shares · 139,554 shares

Expires 2032-02-18

F2 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

SEC source: 0001127602-22-005460 · form4.xml · derivative · entry 3

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 2,375 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into ordinary shares on a one-for-one basis.

F2 · derivative.exercise_date: This award is fully vested in accordance with its terms.

F2 · derivative.expiration_date: This award is fully vested in accordance with its terms.

SEC source: 0001127602-22-005460 · form4.xml · nonDerivative · entry 2

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,564

SEC source: 0001127602-22-005460 · form4.xml · nonDerivative · entry 1

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,389

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into ordinary shares on a one-for-one basis.

SEC source: 0001127602-21-025404 · form4.xml · nonDerivative · entry 2

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,014

SEC source: 0001127602-21-025404 · form4.xml · nonDerivative · entry 1

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,038

F1 · price: These ordinary shares were acquired by the reporting person as a result of the partial vesting of performance-vesting restricted stock unit awards ("PRSUs") granted to the reporting person on February 20, 2020. The vesting of this portion of the PRSUs was triggered by the achievement of certain pre-specified pipeline performance goals.

SEC source: 0001127602-21-015189 · form4.xml · derivative · entry 3

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 34,503 shares

Expires 2021-05-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.